Genentech v. Sun Pharma: Vismodegib Patent Dispute Dismissed

Case Overview

The Parties

The Patent at Issue

This action involved U.S. Patent No. 9,278,961 B2, covering compositions and related claims pertaining to vismodegib, a smoothened (SMO) antagonist used in basal cell carcinoma treatment. The patent is registered with the U.S. Patent and Trademark Office (USPTO).

The Accused Product

Sun Pharma’s vismodegib capsules at 150 mg strength — a generic equivalent targeting Genentech’s branded ERIVEDGE® — formed the basis of the infringement allegations. ERIVEDGE® addresses a limited but defined oncology market with no widely available therapeutic alternatives.

Legal Representation

Plaintiff Genentech: Robinson Miller LLC (attorneys Bradley Alan Suiters and Keith J. Miller)
Defendant Sun Pharma: Kratz & Barry, LLP (attorneys Michael P. Hogan, R. Touhey Myer, and Timothy H. Kratz)

Litigation Timeline & Procedural History

The complaint was filed on June 13, 2025, in the U.S. District Court for the District of New Jersey — a venue with well-established ANDA and pharmaceutical patent litigation infrastructure. The action reached a final resolution on February 25, 2026, yielding a litigation duration of 257 days — approximately eight and a half months.

This timeline is notably shorter than the average pharmaceutical patent infringement case, which frequently extends to multi-year proceedings through claim construction, expert discovery, and trial. The abbreviated duration strongly suggests that the parties reached a private negotiated resolution — possibly a licensing agreement or settlement — that rendered continued litigation unnecessary, leading to the stipulated dismissal.

No motions for summary judgment, claim construction orders, or trial proceedings were disclosed in the provided case data.

The Verdict & Legal Analysis

Outcome

The case was resolved via stipulated dismissal without prejudice, with the court directing the clerk to enter the stipulation and order immediately. Critically:

• • All claims, counterclaims, affirmative defenses, and demands were dismissed
• • No costs, disbursements, or attorneys’ fees were awarded to any party
• • The dismissal was entered without prejudice, preserving the theoretical ability of either party to reinitiate proceedings

No damages figure was disclosed. No injunctive relief was granted or denied on the merits.

Verdict Cause Analysis

The infringement action never proceeded to a merits determination. The mutual dismissal without prejudice and without fees is a hallmark of cases resolved through confidential settlement or licensing negotiations occurring parallel to, or shortly after, formal litigation. The equal fee-bearing arrangement (no costs to either side) is consistent with a negotiated exit rather than a capitulation by either party.

From a legal standpoint, the dismissal without prejudice on U.S. Patent No. 9,278,961 B2 means the patent’s validity and infringement were never adjudicated. This is a meaningful distinction: the patent survives with its presumption of validity intact, and Sun Pharma received no judicial vindication of its non-infringement or invalidity positions.

Legal Significance

The “without prejudice” designation carries strategic weight. Genentech retains the right to re-assert this patent — or related continuation patents — against Sun Pharma or other generic entrants should circumstances change. Conversely, Sun Pharma’s affirmative defenses (presumably including invalidity and non-infringement contentions standard in ANDA-related litigation) were withdrawn without creating any collateral estoppel or issue preclusion.

This outcome also reflects a broader litigation pattern in pharmaceutical patent disputes: parties frequently find economic resolution before courts are required to rule on technically complex infringement and validity questions, preserving strategic optionality for both sides.

Strategic Takeaways

For Patent Holders (Branded Pharma/Genentech): Early-stage settlement or licensing in pharmaceutical patent disputes can preserve both patent validity and commercial terms without the uncertainty of litigation outcomes. Retaining a “without prejudice” posture protects future enforcement rights.

For Accused Infringers (Generic Manufacturers/Sun Pharma): A negotiated exit with no fee award and no prejudice avoids the risk of an adverse claim construction ruling that could affect not only this product but the defendant’s broader ANDA pipeline strategy. Design-around considerations and IPR petitions at the USPTO remain alternative tools when litigation risk is high.

For R&D and Regulatory Affairs Teams: The resolution of this matter does not establish a freedom-to-operate (FTO) clearance for vismodegib formulations under U.S. Patent No. 9,278,961 B2. Any party seeking to commercialize vismodegib generics should conduct independent FTO analysis, given the patent’s continued validity.

Industry & Competitive Implications

The Genentech v. Sun Pharma dismissal reflects an ongoing pattern in oncology drug patent enforcement: branded manufacturers aggressively defend hedgehog pathway and targeted therapy patents while generic challengers weigh ANDA litigation costs against settlement economics.

ERIVEDGE® (vismodegib) occupies a niche but durable market position as the first SMO inhibitor approved for basal cell carcinoma. Generic entry at commercially meaningful scale depends on resolving patent exclusivity — and confidential licensing arrangements of the type this dismissal pattern suggests can reshape generic launch timing without any public adjudication.

For the broader pharmaceutical IP sector, this case underscores that the District of New Jersey remains the venue of choice for pharmaceutical patent enforcement, and that 257-day resolutions in this space often reflect pre-trial business negotiations rather than litigation attrition.

Companies holding composition-of-matter or formulation patents in specialty oncology should monitor continuation patent filings from innovators like Genentech, as a single dismissed action does not foreclose subsequent enforcement on related patent claims.